Here, we analyzed serum CXCL13 and BAFF levels in NMO and MS patients during remission and explored correlations of CXCL13 and BAFF levels with the clinical features and immunosuppressive treatment of NMO patients. This evidence concerns the gene TNFSF13B and myeloid sarcoma.